Total accumulated dose of cisplatin and EXTREME regimen for recurrent and metastatic head and neck carcinoma

Abstract

Introduction: The EXTREME regimen has been reported to result in significant prolongation of survival for unresectable recurrent and metastatic head and neck cancers.
Method: We performed a retrospective analysis of prognostic factors in 28 patients who underwent the EXTREME regimen between 2015 and 2019 based on patient background factors and treatment content.
Results: One-year PFS was 16％ and one-year OS was 60％. One-year OS was 79％ in patients with total cisplatin accumulation of more than 300mg/m2, and those with chemoradiotherapy before recurrence tended to have total cisplatin accumulation of more than 300mg/m2.
Discussion: Patients who received chemoradiotherapy before recurrence tended to be able to receive cisplatin at 300mg/m2 or more, and those who received a sufficient amount of cisplatin resulted in long-term survival.